EN
Home/Answers/Body fat percentage
ALLAll countries Medicines

Why isn't body fat % changing on tirzepatide or semaglutide?

What we checked15 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Body fat percentage falls more slowly than weight on tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy), because lean mass is lost too. In the STEP 1 trial's scan study, body fat fell from 43.4% to 39.4% over 68 weeks. In one diet study, a bioimpedance body fat scale showed about 3 points less fat loss than a DXA scan.

Why does body fat percentage move more slowly than weight?

Body fat percentage is fat as a share of total weight,4 so it falls only when fat makes up more of the weight you lose than it did of your starting weight (our own arithmetic).

In SURMOUNT-1’s scan substudy, about three-quarters of the weight lost on tirzepatide was fat and a quarter was lean mass.3 Placebo showed the same split.3 Lean mass there means everything except fat and bone, including muscle, organs, tendons and water.3

Here is our own worked example, using that three-to-one split.3 Take a 100 kg person carrying 45 kg of fat, which is 45%. After losing 5 kg, about 41 kg of fat remains in 95 kg, or about 43%. After losing 20 kg, 30 kg of fat remains in 80 kg, or 37.5%. The first 5 kg moves body fat by under 2 points.

How much did body fat percentage fall in the trials?

In the STEP 1 DXA scan substudy, body fat fell from 43.4% to 39.4% over 68 weeks on Wegovy, the Canadian Wegovy label reports.4

On placebo it barely moved, from 44.6% to 44.2%.4 People on Wegovy lost 8.4 kg of fat and 5.3 kg of lean mass.4 Their lean share of body weight rose from 53.9% to 57.4%, even though lean mass fell.4 So a rising “muscle %” does not prove muscle was gained. The Australian Wegovy label gives a mean fall of 3.9 percentage points.5

In SURMOUNT-1, fat mass fell 34% on tirzepatide against 8% on placebo over 72 weeks.3 Body weight fell 21% against 5%.3 Labels in the US, UK, EU, Canada and Australia say fat falls more than lean mass, or that most weight lost is fat.121112131415

The risks, in brief Lean mass falls along with fat, and a joint advisory lists muscle and bone loss as a challenge of GLP-1 treatment.9 The US Wegovy label warns that substantial or rapid weight loss can raise the risk of gallbladder disease.2 Side effects and risks (US guide)

Can a home body fat scale show the change?

Body composition scales that use bioimpedance (BIA) often read differently from a DXA scan (a low-dose X-ray that measures fat, lean mass and bone), and in one study the gap shrank as weight fell.6

In a 6-month weight loss study of 189 adults in Taiwan, a standing scale with hand and foot electrodes read lower than DXA.6 The gap was about 5 points at the start and about 2 points at the end.6 So the scale showed about 3 points less fat loss than DXA.6 The authors named hydration as one source of error.6

In the NUGENOB study, BIA and DXA results for change over 10 weeks of weight loss differed widely from person to person.7 The authors said the two methods cannot be used interchangeably.7

Healthdirect, Australia’s government health service, says waist size is a guide to deep belly (visceral) fat.8 It adds that waist size can be less reliable in people living with obesity.8

What do people on GLP-1 medicines report about body fat percentage?

From public patient forums: 66 Reddit threads in r/Zepbound, r/mounjarouk, r/Semaglutide, r/Mounjaro, r/Ozempic and r/WegovyWeightLoss, posted from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the studies Many say their home scale’s body fat figure was far from a DXA result, in either direction. Two studies found bioimpedance and DXA disagree.67
  • Partly matches one study Several say readings jump from day to day and blame hydration, food or exercise. One study names hydration as a source of error, but did not test daily swings.6
  • Matches the label Several point out that muscle % can rise while muscle mass falls. In STEP 1, the lean share rose while lean mass fell.4
  • Partly matches the trial Several describe notable lean loss on repeat scans, while several others say lean mass held well, so reports differ. In SURMOUNT-1, lean mass made up about a quarter of the weight lost, on average.3

Advice people share

  • Partly matches two studies Many advise using home scales only for trends, weighed under the same conditions. One study found a bioimpedance scale less accurate for change during weight loss.6 Another found it useful for change only across a group, not for one person.7
  • Partly matches the advisory Many advise resistance training and protein early. A joint advisory recommends resistance training and an appropriate diet to preserve muscle and bone. The summary we read does not mention protein or timing.9
  • Partly matches Healthdirect Many track waist size, strength, photos or clothing fit instead. Healthdirect calls waist size a guide to visceral fat, but less reliable with obesity.8
  • Label says otherwise Several describe changing doses on their own. The US Zepbound label raises doses in 2.5 mg steps after at least 4 weeks, up to 15 mg weekly.1

In your country

Body fat percentage works the same way everywhere, while the brands sold and the labels we opened differ by country.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The answer above applies.

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The answer above applies.

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies. We read the English EU product information for Mounjaro and Wegovy.

Emergency number: 15 or 112

Side effects and risks in France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies. We read the English EU product information for Mounjaro and Wegovy.

Emergency number: 112

Side effects and risks in Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We did not open an Indian label for this page, so it relies on the US, UK, EU, Canadian and Australian labels.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a Saudi label for this page, so it relies on the US, UK, EU, Canadian and Australian labels.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a UAE label for this page, so it relies on the US, UK, EU, Canadian and Australian labels.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: The answer above applies.

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number Severe abdominal pain or pressure, severe or persistent vomiting or diarrhoea, fainting, breathing problems, or thoughts of suicide are emergency warning signs, according to the American College of Emergency Physicians.10 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you have nausea, vomiting or diarrhoea that does not go away, which can cause dehydration and kidney problems.1 The same applies to upper stomach pain, fever, yellowing of the skin or eyes, or clay-coloured stools, which can be gallbladder symptoms, the US Zepbound Medication Guide says.1

Read the full picture

Related questions

Did this answer your question?

Sources

  1. US Zepbound (tirzepatide) prescribing information and Medication Guide. Eli Lilly
  2. US Wegovy (semaglutide) prescribing information. DailyMed
  3. Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. Funded by Eli Lilly. PMC11965027
  4. Canadian Wegovy (semaglutide injection) Product Monograph, Effect on Body Composition (STEP 1 substudy). Health Canada Drug Product Database
  5. Australian Wegovy Product Information, Weight loss distribution (STEP 1 substudy). medsinfo
  6. Li YC, et al. Percentage of body fat assessment using bioelectrical impedance analysis and dual-energy X-ray absorptiometry in a weight loss program for obese or overweight Chinese adults. PLoS One. 2013;8(4):e58272. PMC3613423
  7. Verdich C, et al. Changes in body composition during weight loss in obese subjects in the NUGENOB study: comparison of bioelectrical impedance vs. dual-energy X-ray absorptiometry. Diabetes Metab. 2011;37(3):222-229. doi.org/10.1016/j.diabet.2010.10.007
  8. Healthdirect Australia. Body mass index (BMI) and waist circumference. healthdirect.gov.au
  9. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obesity Pillars. 2025;15:100181. doi.org/10.1016/j.obpill.2025.100181
  10. MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians’ warning signs. medlineplus.gov
  11. UK Mounjaro KwikPen (tirzepatide) SmPC. emc
  12. EU Mounjaro (tirzepatide) product information, section 5.1. European Medicines Agency
  13. EU Wegovy (semaglutide) product information, section 5.1. European Medicines Agency
  14. Canadian Zepbound (tirzepatide injection) Product Monograph. Health Canada Drug Product Database
  15. Australian Mounjaro (tirzepatide) Product Information. medsinfo

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, checked on Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write